1Bocci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli IrLstitute in 57 patients treated with cisplatin, doxorubicin, and a high dose of rnethotrexate and ifosfamide. Ann Oncol, 2003 . 14(7) : 1126-1134.
2Bacci G, Ferrari S, Mercuri M, et al. Neoadjuvanl chemotherapy for osteosarcoma of the extremities in patients aged 41-60 years: outcome in 34 cases treated with adriamydn, dsplatinum and ifosfamide between 1984 and 1999. Acta Orthop, 2007; 78(3):377-384.
3Ferrari S, Smeland S, Mercuri M, et al. Nenadjuvant chemotherapy with highdose Ifosfamide, high-dose methotrexate, dsplatin, and doxorubidn for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Gmups J Clin Oncol, 2005. 23(34):8845-8852.
4Chi SN, Conklin LS, Qin J, et al. The patterns of relapse in osteosarcoma: the Memorial Sloan-Kettering experience. Pecliatr Blood Cancer, 20(0; 42(1) ,46-51.
5Ferrari C, Bohling T, Benassi M, et al. Secondary tumors in bone sarcomas after treatment with chemotherapy. Cancer Detcet Prev, 1999. 23(5) :368-374.
6Bacci G, Ferrari C, I.onghi A, et al. Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol, 2006; 28(12):774-780.
7Hicks MJ, Roth JR, Kozinetz CA, et al. Clinicopathologic features of osteosarcoma in patients with Rothmund-Thomson syndrome. J Clin Oncol, 2007; 25(4) : 370-375.
8German J. Bloom's syndrome. XX. The first 100 cancers Cancer Genet Cytogenet, 1997; 93(1):100-106.
9Manoukian S, Peissel B, Pensotti V, et al. Germline mutations of TP53 and. BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer, 2007; 43(3) :601-606.
10Lavigueur A, Maltby V, Mock D, et al. High inddence of lung, bone, and lymphoid tumors in trartsgenic mice overexpresing mutant alleles of the p53 oncogene Mol Cell Biol, 1989; 9(9) :3987-3991.
